2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2126

Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
Abstract Number: 2201

Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Abstract Number: 1824

Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials
Abstract Number: 847

Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension
Abstract Number: 2031

Tuberculosis in Patients Treated with Biological Drugs
Abstract Number: 558

Tuberculosis Risk Among Patients with Rheumatoid Arthritis in a United States Claims Database Initiating Abatacept and Other Biologic Disease-Modifying Antirheumatic Drugs: Analyses Using International Classification of Diseases Codes and a Published Claims Algorithm
Abstract Number: 2911

Tubulointerstitial Involvement in Lupus Nephritis
Abstract Number: 1038

Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Abstract Number: 2842

Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Abstract Number: 2059

Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Abstract Number: 1023

Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma
Abstract Number: 910

Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 1313

Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry
Abstract Number: 382

Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
Abstract Number: 2225

Twitter and Rheumatology: Significant and Incremental Growth in Usage

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].